Wilfredo Martin Casapia Morales

Dr. Wilfredo Martin Casapia Morales

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2012 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
SPSimon Pollett
Simon Pollett
CRClaudio Rocha
Claudio Rocha
RZRito Zerpa
Rito Zerpa
LPLilian Patiño
Lilian Patiño
AVAugusto Valencia
Augusto Valencia
MKMatthew Kasper
Matthew Kasper
Campylobacter jejuni and Campylobacter coli are food-borne pathogens of great importance and feature prominently in the etiology of developing world enteritis and travellers’ diarrhoea. Increasing antimicrobial resistant Campylobacter prevalence has been described globally, yet data from Peru is limited. Our objective was to describe the prevalence trends of fluoroquinolone and macrolide-resistant C. jejuni and C. coli stool isolates from three regions in Peru over a ten-year period.

1 September 2007 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
FPFalgunee K. Parekh
Falgunee K. Parekh
JHJean N. Hernandez
Jean N. Hernandez
DKDonald J. Krogstad
Donald J. Krogstad
WMWilfredo Martin Casapia Morales
Wilfredo Martin Casapia Morales
OBOralee H. Branch
Oralee H. Branch
The Amazon region of Iquitos, Peru is hypoendemic for Plasmodium vivax and P. falciparum. There is limited information regarding the epidemiology of malaria during pregnancy in this region. Passive surveillance for clinical malaria among pregnant women was conducted in eight health posts in 2004 and 2005. Community-based active surveillance was conducted to determine the incidence of malarial infection among pregnant women in the community of Zungarococha in 2004 and 2005. Passive surveillance demonstrated that pregnant women had a prevalence of clinical malaria of 7.5% in 2004 and 6.6% in 2005 compared with 20.6% and 22.4% of the total population. Active surveillance showed that pregnant women were 2.3 (95% confidence interval = 1.32–3.95, P = 0.004) times more likely to have a P. falciparum infection compared with non-pregnant women. This study demonstrated that because of detection bias, passive surveillance underestimates the burden of malarial infection during pregnancy, and that subclinical malarial infections may occur frequently among pregnant women in this region. Furthermore, pregnant women in this low-transmission and P. vivax–dominant setting, experience an increased risk for P. falciparum infection, but not P. vivax infection.

14 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDaniel Reeves
Daniel Reeves
BMBryan Mayer
Bryan Mayer
ADAllan DeCamp
Allan DeCamp
YHYunda Huang
Yunda Huang
BZBo Zhang
Bo Zhang
SESrilatha Edupuganti
Srilatha Edupuganti
The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) demonstrated that passive administration of the broadly neutralizing monoclonal antibody VRC01 could prevent some HIV-1 acquisition events. Here, we use mathematical modeling in a post hoc analysis to demonstrate that VRC01 influenced viral loads in AMP participants who acquired HIV. Instantaneous inhibitory potential (IIP), which integrates VRC01 serum concentration and VRC01 sensitivity of acquired viruses in terms of both IC50 and IC80, follows a dose-response relationship with first positive viral load (p = 0.03), which is particularly strong above a threshold of IIP = 1.6 (r = -0.6, p = 2e-4). Mathematical modeling reveals that VRC01 activity predicted from in vitro IC80s and serum VRC01 concentrations overestimates in vivo neutralization by 600-fold (95% CI: 300–1200). The trained model projects that even if future therapeutic HIV trials of combination monoclonal antibodies do not always prevent acquisition, reductions in viremia and reservoir size could be expected.

28 February 2013 in BMC Public Health
Verified
Journal Article
Open access
PDF file
FGfor the Peruvian HIV Sentinel Surveillance Working Group
for the Peruvian HIV Sentinel Surveillance Working Group
SNSharita Nagaraj
Sharita Nagaraj
ESEddy R Segura
Eddy R Segura
JPJesus Peinado
Jesus Peinado
KKKelika Anne Konda
Kelika Anne Konda
JLJavier R. Lama
Javier R. Lama
Knowledge of a sex partner’s HIV serostatus can influence sexual behavior and inform harm-reduction strategies. We sought to determine how often Peruvian men who have sex with men (MSM) and transgender women (TW) knew the HIV serostatus of their sex partners, if this knowledge was associated with any predictive factors or unprotected anal intercourse (UAI), and if UAI was associated with partner serostatus.

20 November 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
EKEsper G. Kallas
Esper G. Kallas
NGNicole A. Grunenberg
Nicole A. Grunenberg
CYChenchen Yu
Chenchen Yu
BMBryce A. Manso
Bryce A. Manso
GPGiuseppe Pantaleo
Giuseppe Pantaleo
NFNicole Frahm
Nicole Frahm
Antigenic competition in CD4 + T cell responses occurs in HIV vaccine recipients.

6 December 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
SKShelly Karuna
Shelly Karuna
SLShuying Sue Li
Shuying Sue Li
SGShannon Grant
Shannon Grant
SWStephen R. Walsh
Stephen R. Walsh
IFIan Frank
Ian Frank
FTfor the HVTN 405/HPTN 1901 Study Team
for the HVTN 405/HPTN 1901 Study Team
Background: People infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) experience a wide range of clinical manifestations, from asymptomatic and mild illness to severe illness and death, influenced by age and a variety of comorbidities. Neutralizing antibodies (nAbs) are thought to be a primary immune defense against the virus. Large, diverse, well-characterized cohorts of convalescent individuals provide standardized values to benchmark nAb responses to past SARS-CoV-2 infection and define potentially protective levels of immunity.Methods and findings: This analysis comprises an observational cohort of 329 HIV–seronegative adults in the United States (n= 167) and Peru (n= 162) convalescing from SARS-CoV-2 infection from May through October 2020. The mean age was 48 years (range 18 to 86), 54% of the cohort overall was Hispanic, and 34% identified as White. nAb titers were measured in serum by SARS-CoV-2.D614G Spike-pseudotyped virus infection of 293T/ACE2 cells. Multiple linear regression was applied to define associations between nAb titers and demographic variables, disease severity and time from infection or disease onset, and comorbidities within and across US and Peruvian cohorts over time. nAb titers peaked 28 to 42 days post-diagnosis and were higher in participants with a history of severe Coronavirus Disease 2019 (COVID-19) (p< 0.001). Diabetes, age >55 years, male sex assigned at birth, and, in some cases, body mass index were also independently associated with higher nAb titers, whereas hypertension was independently associated with lower nAb titers. nAb titers did not differ by race, underlying pulmonary disease or smoking. Two months post-enrollment, nAb ID50 (ID80) titers declined 3.5 (2.8)-fold overall. Study limitations in this observational, convalescent cohort include survivorship bias and missing early viral loads and acute immune responses to correlate with the convalescent responses we observed.Conclusions: In summary, in our cohort, nAb titers after SARS-CoV-2 infection peaked approximately 1 month post-diagnosis and varied by age, sex assigned at birth, disease severity, and underlying comorbidities. Our data show great heterogeneity in nAb responses among people with recent COVID-19, highlighting the challenges of interpreting natural history studies and gauging responses to vaccines and therapeutics among people with recent infection. Our observations illuminate potential correlations of demographic and clinical characteristics with nAb responses, a key element for protection from COVID-19, thus informing development and implementation of preventative and therapeutic strategies globally.Trial registration: ClinicalTrials.govNCT04403880.